Purple Biotech (XTAE:PPBT) Growth Rank : 0 (As of Jun. 10, 2024)

View and export this data going back to 1978. Start your Free Trial

What is Purple Biotech Growth Rank?

Purple Biotech has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Purple Biotech Growth Rank Related Terms

Thank you for viewing the detailed overview of Purple Biotech's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Purple Biotech (XTAE:PPBT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Purple Biotech Ltd (XTAE:PPBT) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

PPBT:USA 1YI1:Germany

Address

4 Oppenheimer Street, Science Park, Rehovot, ISR, 7670104

Website

https://www.purple-biotech.com

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219 and CM24.